4448-75-3

Usage

Uses

Used in Organic Chemistry:
(Hydroxymethyl)cycloheptane is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure allows it to be a versatile building block in the synthesis of complex molecules, contributing to the development of new chemical entities and materials.
Used in Pharmaceutical Industry:
(Hydroxymethyl)cycloheptane is used as a key component in the synthesis of pharmaceutical compounds. Its presence in the molecular structure can influence the properties and activities of the resulting drug molecules, making it a valuable asset in the development of new medications.
Used in Material Science:
(Hydroxymethyl)cycloheptane is used as a precursor in the development of new materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of materials with tailored characteristics, such as improved strength, flexibility, or chemical resistance.
Used in Research and Development:
(Hydroxymethyl)cycloheptane is used as a research compound in academic and industrial laboratories. Its unique structure and reactivity make it an interesting subject for studies aimed at understanding the fundamental principles of organic chemistry and exploring new synthetic methodologies.

InChI:InChI=1/C8H16O/c9-7-8-5-3-1-2-4-6-8/h8-9H,1-7H2

Upstream product

• 1460-16-8 cycloheptanoic acid 
• 3292-09-9 1-hydroxymethyl-1-cycloheptene 
• 185-85-3 1-Oxa-spiro[2.6]nonane 
• 107-31-3 Methyl formate 
• 628-92-2 Cycloheptene 
• 78371-04-7 2-Cycloheptylmethoxy-tetrahydro-pyran 
• 78371-03-6 Benzyloxymethyl-cycloheptane 
• 917-64-6 methyl magnesium iodide 
• 502-42-1 cycloheptanone 
• 50-00-0 formaldehyd 
• 1614-73-9 4-cycloheptene-1-carboxylic acid 
• 201230-82-2 carbon monoxide 
• 60433-00-3 methyl cycloheptanecarboxylate 
• 4277-29-6 cycloheptanecarboxaldehyde 

Downstream Products

• 3814-32-2 1-(bromomethyl)cycloheptane 
• 931-88-4 cis-Cyclooctene 
• 40213-25-0 <4-Brom-benzolsulfonyl-oxymethyl>-cycloheptan, Cycloheptanemethyl-brosylate 
• 1453-25-4 1-methylcycloheptene 
• 4277-29-6 cycloheptanecarboxaldehyde 
• 191664-06-9 4-Chloro-benzenesulfonic acid cycloheptylmethyl ester 
• 16472-98-3 cycloheptylmethyl 4-methylbenzenesulfonate 
• 17595-82-3 cycloheptylmethyl p-nitrobenzenesulfonate 
• 226723-96-2 1--4,8-N-(2-mesitylenesulfonyl)-11--4,8-diazaundecane 

Relevant academic research and scientific papers

Me3SI-promoted chemoselective deacetylation: a general and mild protocol

A Me3SI-mediated simple and efficient protocol for the chemoselective deprotection of acetyl groups has been developedviaemploying KMnO4as an additive. This chemoselective deacetylation is amenable to a wide range of substrates, tolerating diverse and sensitive functional groups in carbohydrates, amino acids, natural products, heterocycles, and general scaffolds. The protocol is attractive because it uses an environmentally benign reagent system to perform quantitative and clean transformations under ambient conditions.

Production of oxygen-containing alicyclic compounds (by machine translation)

[Problem] to provide, in a one-step reaction synthesizes an alicyclic compound containing oxygen, high yield production of oxygen-containing compound is a cycloaliphatic. [Solution] one or more hydroxy or carbonyl group 2, or a hydroxyl group having the carbon number of 5 or more aliphatic carbonyl group 2 in accordance with one or more oxygen-containing compound, a basic catalyst is brought into contact with an oxygen-containing alicyclic compound by cyclodehydration reaction, oxygen-containing alicyclic compound. [Drawing] no (by machine translation)

Vicinal, Double C-H Functionalization of Alcohols via an Imidate Radical-Polar Crossover Cascade

A double functionalization of vicinal sp3 C-H bonds has been developed, wherein a β amine and γiodide are incorporated onto an aliphatic alcohol in a single operation. This approach is enabled by an imidate radical chaperone, which selectively affords a transient β alkene that is amino-iodinated in situ. Overall, the radical-polar-crossover cascade entails the following key steps: (i) β C-H iodination via 1,5-hydrogen atom transfer (HAT), (ii) desaturation via I2 complexation, and (iii) vicinal amino-iodination of an in situ generated allyl imidate. The synthetic utility of this double C-H functionalization is illustrated by conversion of aliphatic alcohols to a diverse collection of α,β,γsubstituted products bearing heteroatoms on three adjacent carbons. The radical-polar crossover mechanism is supported by various experimental probes, including isotopic labeling, intermediate validation, and kinetic studies.

COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS

The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, schizophrenia, cognitive impairment or cognitive impairment associated with schizophrenia (CIAS). Separate aspects of the invention are directed to the combined use of said compounds for the treatment of psychiatric and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of psychiatric and/or cognitive disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES

The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disease, Parkinson's Disease or Huntington's Disease. Separate aspects of the invention are directed to the combined use of said compounds for the treatment of neurodegenerative and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of neurodegenerative disorders.

BIARYL PYRAZOLES AS NRF2 REGULATORS

The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

Efficient carbon-supported heterogeneous molybdenum-dioxo catalyst for chemoselective reductive carbonyl coupling

Reductive coupling of various carbonyl compounds to the corresponding symmetric ethers with dimethylphenylsilane is reported using a carbon-supported dioxo-molybdenum catalyst. The catalyst is air- and moisture-stable and can be easily separated from the reaction mixture for recycling. In addition, the catalyst is chemoselective, thus enabling the synthesis of functionalized ethers without requiring sacrificial ligands or protecting groups.

Chemoselective continuous-flow hydrogenation of aldehydes catalyzed by platinum nanoparticles dispersed in an amphiphilic resin

A chemoselective continuous-flow hydrogenation of aldehydes catalyzed by a dispersion of platinum nanoparticles in an amphiphilic polymer (ARP-Pt) has been developed. Aromatic and aliphatic aldehydes bearing various reducible functional groups, such as keto, ester, or amide groups, readily underwent flow hydrogenation in aqueous solutions within 22 s in a continuous-flow system containing ARP-Pt to give the corresponding primary benzylic or aliphatic alcohols in ≤99% yield with excellent chemoselectivity. Moreover, the long-term continuous-flow hydrogenation of benzaldehyde for 8 days was realized, and the total turnover number of the catalyst reached 997. The flow hydrogenation system provides an efficient and practical method for the chemoselective hydrogenation of aldehydes bearing reducible functional groups.

AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS

Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

IMIDAZOPYRAZINONES AS PDE1 INHIBITORS

The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.